Cargando…
Inhibition of stromal‐interacting molecule 1‐mediated store‐operated Ca(2+) entry as a novel strategy for the treatment of acquired imatinib‐resistant gastrointestinal stromal tumors
Imatinib has revolutionized the treatment of gastrointestinal stromal tumors (GIST); however, primary and secondary resistance to imatinib is still a major cause of treatment failure. Multiple mechanisms are involved in this progression. In the present study, we reported a novel mechanism for the ac...
Autores principales: | Yang, Ziyi, Pan, Lijia, Liu, Shilei, Li, Fengnan, Lv, Wenjie, Shu, Yijun, Dong, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125455/ https://www.ncbi.nlm.nih.gov/pubmed/29957833 http://dx.doi.org/10.1111/cas.13718 |
Ejemplares similares
-
Molecular Evolution and Functional Divergence of the Ca(2+) Sensor Protein in Store-operated Ca(2+) Entry: Stromal Interaction Molecule
por: Cai, Xinjiang
Publicado: (2007) -
Dynamic S-acylation of the ER-resident protein stromal interaction molecule 1 (STIM1) is required for store-operated Ca(2+) entry
por: Kodakandla, Goutham, et al.
Publicado: (2022) -
RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor
por: Gao, Xiaodong, et al.
Publicado: (2016) -
Local Cytosolic Ca(2+) Elevations Are Required for Stromal Interaction Molecule 1 (STIM1) De-oligomerization and Termination of Store-operated Ca(2+) Entry
por: Shen, Wei-Wei, et al.
Publicado: (2011) -
Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)